Letters to the Editor
Vol. 88 No. 1 (2016)
https://doi.org/10.4081/aiua.2016.1.74

Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 11 April 2016
Published: 31 March 2016
1800
Views
1252
Downloads
TROPIC, Cabazitaxel, Mitoxantrone

Authors

Gianpaolo Perletti
gianpaolo.perletti@uninsubria.it
Department of Biotechnology and Life Sciences, Section of Medical and Surgical Sciences, Università degli Studi dell’Insubria, Busto A., Varese, Italy; Department of Basic Medical Sciences, Ghent University, Ghent, Belgium.
Not available.

Downloads

Download data is not yet available.

How to Cite



Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. (2016). Archivio Italiano Di Urologia E Andrologia, 88(1), 74-75. https://doi.org/10.4081/aiua.2016.1.74

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.